Literature DB >> 33969559

Prevalence of iron deficiency in heart transplant recipients.

Kristine V Brautaset Englund1,2,3, Charlotte M Østby1, Gry Tjønnås1, Einar Gude1,3, Arne K Andreassen1,3, Lars Gullestad1,2,3, Kaspar Broch1,3.   

Abstract

BACKGROUND: Optimal iron management is crucial to marginal patients such as heart transplant recipients. As inflammatory mechanisms are present in transplant recipients, the definition of iron deficiency used in the general population might not be appropriate.
OBJECTIVE: To evaluate the prevalence and determinants of iron deficiency in Norwegian heart transplant recipients.
METHODS: We consecutively assessed iron parameters in all Norwegian heart transplant recipients at their annual follow-up. Several definitions of iron deficiency suggested in the literature were assessed: ferritin <100 µg/L, or ferritin 100-300 µg/L combined with transferrin saturation of <20% (IDHF ); ferritin <100 µg/L (IDF100 ); transferrin saturation of <20% (IDTsat ), and ferritin <30 µg/L (IDF30 ).
RESULTS: 179 of 378 heart transplant recipients (47%) had iron deficiency defined as IDHF . 152 patients (40%) had IDF100 , and 103 patients (27%) had IDTsat . 17 patients (5%) had IDF30 . 88 patients (23%) had a C-reactive protein (CRP) >5.0 µg/L.
CONCLUSION: Iron deficiency defined as IDHF , IDF100, or IDTsat is prevalent in the heart transplant population, while IDF30 is not. Further research is required to identify the mechanisms of iron homeostasis in heart transplant recipients and to establish a definition of iron deficiency suitable for this population.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cardiac transplant recipients; exercise capacity; health-related quality of life; heart transplant recipients; heart transplantation; iron deficiency

Year:  2021        PMID: 33969559     DOI: 10.1111/ctr.14346

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  1 in total

1.  Iron homeostasis in heart transplant recipients randomized to ferric derisomaltose or placebo.

Authors:  Kristine V Brautaset Englund; Charlotte M Østby; Kaspar Broch; Thor Ueland; Pål Aukrust; Einar Gude; Arne K Andreassen; Lars Gullestad
Journal:  Clin Transplant       Date:  2022-06-01       Impact factor: 3.456

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.